Clinical Trial

Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) in adults aged 18 years and older, with the secondary objective being to assess its immunogenicity. The primary objectives of the phase II trial are to evaluate the immunogenicity and safety of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) with different adjuvant ratios in adults aged 60 years and older, with the secondary objective being to evaluate the persistence of immune responses.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-28
Trial Details
NCT Number NCT07582796
Lead Sponsor Ab&B Bio-tech Co., Ltd.JS
Collaborators: Yither Biotech Co., Ltd
Conditions Respiratory Syncytial Virus Infections
Enrollment 470 participants
Start Date 2026-05-14
Primary Completion 2027-09-14 (estimated)
Study Completion 2029-08-14 (estimated)
Updated on ClinicalTrials.gov 2026-05-27